Neuropeptide levels in the basal ganglia of aged common marmosets following prolonged treatment with MPTP |
| |
Authors: | M. D. Taylor M. L. de Ceballos S. Rose P. N. Chong P. Jenner C. D. Marsden |
| |
Affiliation: | (1) Present address: Pharmacology Group, Biomedical Sciences Division, King's College London, Manresa Road, SW3 6LX London, UK;(2) University Department of Clinical Neurology, Institute of Neurology, National Hospital, Queen Square, London, UK |
| |
Abstract: | Summary Aged common marmosets were treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; 0.5–2.0 mg/kg/week i.p.) for 16 or 24 weeks, observed for a total of 30 weeks and then killed for measurement of biochemical pramaters in basal ganglia. The MPTP treatment induced a marked depletion in dopamine, 3,4-dihydroxyphenylacetic acid and homovanillic acid levels in the caudate nucleus and putamen. In contrast, the concentrations of five neuropeptides: [Met5]-enkephalin, [Leu5]-enkephalin, cholecystokinin, substance P and neurotensin as measured by a combined HPLC/RIA method, remained unaltered in all basal ganglia regions examined. Enkephalin precursor levels, as reflected by cryptic [Met5]-enkephalin content, were increased in the putamen, but not in the caudate nucleus, as a consequence of MPTP administration. Cryptic [Leu5]-enkephalin content remained unchanged in the striatum of MPTP treated marmosets. Overall, these results suggest an increase in striatal [Met5]-enkephalin release following chronic MPTP treatment of aged marmosets. However, the chronic treatment of aged marmosets with MPTP does not reproduce the neuropeptide alterations characteristic of Parkinson's disease. |
| |
Keywords: | MPTP peptides basal ganglia common marmoset Parkinson's disease |
本文献已被 SpringerLink 等数据库收录! |
|